Literature DB >> 8582764

Effects of automatic blood volume control over intradialytic hemodynamic stability.

E Mancini1, A Santoro, M Spongano, F Paolini, P Zucchelli.   

Abstract

Due to the crucial role of hypovolemia in the genesis of dialysis-induced hypotension, we have evaluated whether the automatic control of the intradialytic blood volume (BV) decrease along a preset trajectory might be beneficial to the hemodynamic stability during treatment. Five frequently hypotensive HD patients were studied and a 3-period-protocol (A1-B-A2) was adopted, each period lasting 6 sessions per patient. During the B periods the patient BV decrease was kept along a predefined profile, thanks to an automatic system with a retroactive control of both the ultrafiltration rate (UFR) and dialysate conductivity (DC); instead, during the A periods, conventional HD was performed, with linear UFR and constant DC, inducing a spontaneous decrease in BV. The intradialytic BV behaviour was much more stable during the B-periods (-10.2 +/- 1.4% by the end of the treatment) than during the A1 (-11.2 +/- 3%) and A2 periods (-11.5 +/- 2.5%). Only one dialysis-hypotension episode was observed during the B periods, compared to 8 and 5 during the A1 and A2 periods, respectively (p < 0.05). The automatic control of the BV changes during dialysis could improve the intra-treatment cardiovascular stability in critically-ill patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582764

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  1 in total

1.  Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial.

Authors:  Manfred Hecking; Marlies Antlanger; Wolfgang Winnicki; Thomas Reiter; Johannes Werzowa; Michael Haidinger; Thomas Weichhart; Hans-Dietrich Polaschegg; Peter Josten; Isabella Exner; Katharina Lorenz-Turnheim; Manfred Eigner; Gernot Paul; Renate Klauser-Braun; Walter H Hörl; Gere Sunder-Plassmann; Marcus D Säemann
Journal:  Trials       Date:  2012-06-08       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.